Revive Therapeutics Ltd. (CSE: RVV)
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as a Scientific Advisor to guide on the Company’s current and future clinical programs including its research and development strategy for infectious diseases, including the coronavirus disease (“COVID-19”).
Dr. Boulware is an infectious disease physician-scientist and Professor of Medicine, Division of Infectious Diseases and International Medicine at The University of Minnesota. Dr. Boulware is currently the Principal Investigator of a globally recognized COVID-19 clinical trial to determine if post-exposure prophylaxis with hydroxychloroquine can prevent progression development of symptomatic COVID-19 disease after known exposure to the SARS-CoV2 virus (ClinicalTrials.gov Identifier: NCT04308668).
His primary research interests are in meningitis in resource-limited areas including diagnosis, prevention, treatment, and quality improvement initiatives incorporating cost-effectiveness analyses in order to translate knowledge into improved care. Dr. Boulware’s current research is focused on improving the clinical outcomes of HIV-infected persons with cryptococcal meningitis and TB meningitis. Dr. Boulware has active research collaborations in Uganda, South Africa, and Ethiopia leading a multidisciplinary, international research team. He serves on US and WHO panels for cryptococcal meningitis and WHO panels for advanced HIV disease.
VISIT REVIVE THERAPEUTICS PROFILE | HERE
“We are pleased to have Dr. Boulware join us to assist in advancing the research and clinical development of our infectious disease initiatives including exploring the use of Bucillamine as a potential novel treatment for COVID-19,” -said Michael Frank, Chief Executive Officer of Revive.
“Dr. Boulware brings comprehensive clinical expertise in infectious diseases and he will be valuable in guiding our clinical development strategy and product pipeline in infectious diseases.”
“I am excited to assist Revive in their objective in pursuing the clinical development of Bucillamine for infectious diseases and its prospect as a potential solution for COVID-19,”
– said Dr. Boulware.
As previously announced, the Company is exploring the use of Bucillamine as a potential novel treatment for infectious diseases including COVID-19. The Company has applied for a provisional patent with the U.S. Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62/991,996). Revive plans to file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for the use of Bucillamine in the treatment of COVID-19. Parts of the IND will be supported and referenced by the Company’s previous INDs accepted by the FDA and its Phase II grant for the clinical investigation of Bucillamine in the treatment of acute gout flares and cystinuria.
About Revive Therapeutics Ltd.
Revive is a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. Revive’s technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. The Company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantation. With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases.
Sign up for MORE COVID-19 news updates
This article is written and published by The Stocks market
Disclaimer : The Stocks market does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Stocks market are engaged in the business of marketing and advertising companies.
The Stocks market and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.
Disclosure : Revive Therapeutics Ltd is a paid clients of DiableMedia a parent company of The Stock Market.